Search
Dexamethasone Treatment Options
A collection of 1446 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
253 - 264 of 1446
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
Recruiting
This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
12/17/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Active Not Recruiting
Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT.
Pomalidomide is active against MM cells refractory to both bortezomib and lenalidomide, making it an ideal choice for continuation therapy following second ASCT. Adding elotuzumab may increase efficacy and also the durab... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/16/2024
Locations: Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado +2 locations
Conditions: Multiple Myeloma in Relapse
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Active Not Recruiting
This study will evaluate the feasibility of combining four of the most active agents available for the treatment of multiple myeloma. Further the investigators will attempt to assess the activity of this combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Multiple Myeloma
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
Active Not Recruiting
This phase I trial studies the best dose of CB-839 HCl when given together with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back or does not respond to previous treatment. CB-839 HCl and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Yale University, New Haven, Connecticut +4 locations
Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
Completed
The goal of this clinical research study is to learn if light electrical stimulation to the wrist area during surgery is feasible in women having breast surgery.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Post-Operative Nausea and Vomiting, Breast Cancer
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Recruiting
This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/11/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Active Not Recruiting
This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM).
All eligible subjects must be previously treated with at least 3 prior regimens including lenalidomide, pomalidomide, a proteasome inhibitor and an anti-CD38 antibody and be refractory to their last line of therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Local Institution - 103, Duarte, California +53 locations
Conditions: Multiple Myeloma
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer
Active Not Recruiting
This phase II/III trial studies how well physical activity with or without dexamethasone works in reducing cancer-related fatigue in patients with cancer that has spread to other places in the body or has come back. Dexamethasone may decrease the body's immune response. Combining physical activity with dexamethasone may help to treat fatigue in patients with cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
Recruiting
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco, California +18 locations
Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple
DARA RVD For High Risk SMM
Active Not Recruiting
The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma.
The names of the study drugs involved in this study are:
* Daratumumab (also called Darzalex Faspro)
* Bortezomib (also called Velcade)
* Lenalidomide (also called Revlimid)
* Dexamethasone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/07/2024
Locations: Stamford Hospital, Stamford, Connecticut +5 locations
Conditions: High-risk Smoldering Multiple Myeloma, Multiple Myeloma
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Recruiting
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Arizona Clinical Research Center - Hunt - PPDS, Tucson, Arizona +53 locations
Conditions: Solid Tumor
Individualizing Corticosteroid Use in Pneumonia
Recruiting
In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called C- reactive protein (CRP). The overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Pneumonia
253 - 264 of 1446